← Leaderboards
Jason Yustein
Emory University
$9,124,001
Attributed
$12,288,519
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,288,519 · 14
By mechanism
R01$5,492,555 · 5
T32$4,060,175 · 1
R21$2,206,102 · 5
P20$379,111 · 2
R03$150,576 · 1
Top collaborators
- Matthew J Allen4 shared
- Robia G Pautler4 shared
- Atreyi Dasgupta3 shared
- Han Xiao3 shared
- Gregory J. Aune2 shared
- Jennifer J Kohler2 shared
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorIn VivoInnovationUnited States National Institutes Of HealthMissionReportingSignal TransductionCellsSarcomaMalignant NeoplasmsSurvival RateIn VitroEnvironmentDesignMedicineFutureOperative Surgical ProceduresMediatingRegimenTargeted TreatmentAntineoplastic AgentsMolecularHigh RiskChemotherapy
Grant awards (36)
Medical Scientist Training Program$1,283,991
T32 · FY2025 · GM · contact PI
Modeling and targeting intrinsic and extrinsic features of Myc-driven Osteosarcoma$452,549
R01 · FY2025 · CA · contact PI
Dissecting and targeting PAK4 in Ewing sarcoma$439,708
R01 · FY2025 · CA · contact PI
Dissecting and targeting oncogenic functions of PAK4 in high-risk rhabdomyosarcoma$356,758
R01 · FY2025 · CA · contact PI
Medical Scientist Training Program$60,545
T32 · FY2025 · GM · contact PI
Medical Scientist Training Program$1,318,590
T32 · FY2024 · GM · contact PI
Dissecting and targeting PAK4 in Ewing sarcoma$436,850
R01 · FY2024 · CA · contact PI
Identifying and overcoming mechanisms of resistance to effectively target the TBL1/β-catenin signaling axis for high-risk osteosarcoma$376,982
R01 · FY2024 · CA · contact PI
Dissecting and targeting oncogenic functions of PAK4 in high-risk rhabdomyosarcoma$339,158
R01 · FY2024 · CA · contact PI
Medical Scientist Training Program$119,872
T32 · FY2024 · GM · contact PI
Medical Scientist Training Program$1,277,177
T32 · FY2023 · GM · contact PI
Dissecting and targeting oncogenic functions of PAK4 in high-risk rhabdomyosarcoma$371,359
R01 · FY2023 · CA · contact PI
DISSECTING AND TARGETING THE ROLE OF GALNT14 IN HIGH-RISK OSTEOSARCOMA$193,745
R21 · FY2023 · CA · contact PI
Development of Bone-Targeting Antibodies for Ewing Sarcoma Using Genetic Code Expansion$171,527
R21 · FY2023 · CA
DISSECTING AND TARGETING THE ROLE OF GALNT14 IN HIGH-RISK OSTEOSARCOMA$235,869
R21 · FY2022 · CA · contact PI
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines$197,669
R21 · FY2022 · HL
Development of Bone-Targeting Antibodies for Ewing Sarcoma Using Genetic Code Expansion$171,527
R21 · FY2022 · CA
Intratumoral imaging of hypoxia using 1H- and 19F-MRI with redox-responsive Eu-based contrast agents$656,139
R01 · FY2021 · EB
Characterization and targeting the CXCR2-STAT-1/3 axis in metastatic Ewing sarcoma$412,516
R21 · FY2021 · CA
Development of Bone-Targeting Antibodies for Ewing Sarcoma Using Genetic Code Expansion$225,352
R21 · FY2021 · CA
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines$218,685
R21 · FY2021 · HL
Cancer Research Education Program$59,849
P20 · FY2021 · CA · contact PI
1/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education$38,988
P20 · FY2021 · CA · contact PI
Intratumoral imaging of hypoxia using 1H- and 19F-MRI with redox-responsive Eu-based contrast agents$676,601
R01 · FY2020 · EB
Evaluation of PAK inhibitors towards targeting adaptive mechanisms of resistance in high-risk rhabdomyosarcoma$206,843
R21 · FY2020 · CA · contact PI
Cancer Research Education Program$59,848
P20 · FY2020 · CA · contact PI
1/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education$39,264
P20 · FY2020 · CA · contact PI
Intratumoral imaging of hypoxia using 1H- and 19F-MRI with redox-responsive Eu-based contrast agents$683,300
R01 · FY2019 · EB
Evaluation of PAK inhibitors towards targeting adaptive mechanisms of resistance in high-risk rhabdomyosarcoma$172,369
R21 · FY2019 · CA · contact PI
Cancer Research Education Program$58,054
P20 · FY2019 · CA · contact PI
1/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education$31,148
P20 · FY2019 · CA · contact PI
Intratumoral imaging of hypoxia using 1H- and 19F-MRI with redox-responsive Eu-based contrast agents$703,151
R01 · FY2018 · EB
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma$75,288
R03 · FY2018 · CA · contact PI
Cancer Research Education Program$59,848
P20 · FY2018 · CA · contact PI
1/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education$32,112
P20 · FY2018 · CA · contact PI
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma$75,288
R03 · FY2017 · CA · contact PI